Sant David W, Nelson Christina A, Petrie JoAnn, Blotter Jonathan D, Feland J Brent, Adams Daniel, Burrows Marc, Yorgason Jordan T, Schilaty Nathan D, Manwaring Kim H, Bills Kyle B, Steffensen Scott C
Noorda College of Osteopathic Medicine, Provo, UT USA.
Brigham Young University, Provo, UT, USA.
J Psychiatry Cogn Behav. 2024;8(1). doi: 10.29011/2574-7762.000073. Epub 2024 Mar 21.
Opioid use disorder (OUD)-associated overdose deaths have reached epidemic proportions worldwide. An important driving force for relapse is anxiety associated with opioid withdrawal. We hypothesized that our new technology, termed heterodyned whole-body vibration (HWBV) would ameliorate anxiety associated with OUD.
Using a randomized, placebo (sham)-controlled, double-blind study design in an NIH-sponsored Phase 1 trial, we evaluated 60 male and 26 female participants diagnosed with OUD and undergoing treatment at pain and rehabilitation clinics. We utilized the Hamilton Anxiety Scale (HAM-A) and a daily visual analog scale anxiety rating (1-10) to evaluate anxiety. Subjects were treated for 10 min 5X/week for 4 weeks with either sham vibration (no interferential beat or harmonics) or HWBV (beats and harmonics). The participants also completed a neuropsychological test battery at intake and discharge.
In OUD subjects with moderate anxiety, there was a significant improvement in daily anxiety scores in the HWBV group compared to the sham treatment group (p=3.41 × 10). HAM-A scores in OUD participants at intake showed moderate levels of anxiety in OUD participants (HWBV group: 15.9 ± 1.6; Sham group: 17.8 ± 1.6) and progressively improved in both groups at discharge, but improvement was greater in the HWBV group (p=1.37 × 10). Furthermore, three indices of neuropsychological testing (mental rotations, spatial planning, and response inhibition) were significantly improved by HWBV treatment.
These findings support HWBV as a novel, non-invasive, non-pharmacological treatment for anxiety associated with OUD.
阿片类物质使用障碍（OUD）相关的过量死亡在全球已达到流行程度。复发的一个重要驱动因素是与阿片类物质戒断相关的焦虑。我们假设我们的新技术，即外差式全身振动（HWBV），将改善与OUD相关的焦虑。
在一项由美国国立卫生研究院资助的1期试验中，采用随机、安慰剂（假手术）对照、双盲研究设计，我们评估了60名男性和26名女性参与者，他们被诊断为患有OUD，并在疼痛和康复诊所接受治疗。我们使用汉密尔顿焦虑量表（HAM - A）和每日视觉模拟量表焦虑评分（1 - 10）来评估焦虑。受试者每周接受5次、每次10分钟的治疗，持续4周，治疗方式为假振动（无干扰节拍或谐波）或HWBV（节拍和谐波）。参与者在入组和出院时还完成了一套神经心理测试。
在患有中度焦虑的OUD受试者中，与假治疗组相比，HWBV组的每日焦虑评分有显著改善（p = 3.41×10）。入组时OUD参与者的HAM - A评分显示出中度焦虑水平（HWBV组：15.9±1.6；假手术组：17.8±1.6），两组在出院时均逐渐改善，但HWBV组的改善更大（p = 1.37×10）。此外，HWBV治疗显著改善了神经心理测试的三个指标（心理旋转、空间规划和反应抑制）。
这些发现支持HWBV作为一种治疗与OUD相关焦虑的新型、非侵入性、非药物疗法。
